We are currently working on the hit-to-lead process for KRAS and Cyclin D1 (CCND1) proteins in the biology lab.
Both are well-known oncological targets.
The PPI-FIT approach, docking the small molecule to the folding intermediate state, allows us to differentiate from the drugs on the market or in clinical trials.
In the case of KRAS, we are a developing a panKRAS degrader that can face all types of KRAS mutations and related cancers while leaving unaltered loads of NRAS and HRAS in the cell. As far as Cyclin D1 is concerned, we directly promote its degradation instead of targeting the cyclin-dependent kinases CDK4/6, thus pursuing a better selectivity index.
An undisclosed number of targets has already been identified and characterized at the computational level.